Arash Hatefi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9389254/publications.pdf

Version: 2024-02-01

31 papers	859 citations	430874 18 h-index	477307 29 g-index
31 all docs	31 docs citations	31 times ranked	1225 citing authors

#	Article	IF	Citations
1	Gadolinium-labeled affibody-XTEN recombinant vector for detection of HER2+ lesions of ovarian cancer lung metastasis using quantitative MRI. Journal of Controlled Release, 2021, 337, 132-143.	9.9	6
2	Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis. Journal of Controlled Release, 2019, 311-312, 273-287.	9.9	17
3	Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells. Biomaterials, 2018, 152, 1-14.	11.4	14
4	Evaluation of genotoxicity and mutagenic effects of vector/DNA nanocomplexes in transfected mesenchymal stem cells by flow cytometry. Acta Biomaterialia, 2018, 74, 236-246.	8.3	5
5	A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer. Cancer Medicine, 2018, 7, 3630-3641.	2.8	9
6	Production of low-expressing recombinant cationic biopolymers with high purity. Protein Expression and Purification, 2017, 134, 11-17.	1.3	7
7	Anin vitrodemonstration of overcoming drug resistance in SKOV3 TR and MCF7 ADR with targeted delivery of polymer pro-drug conjugates. Journal of Drug Targeting, 2017, 25, 436-450.	4.4	3
8	Development of a Recombinant Multifunctional Biomacromolecule for Targeted Gene Transfer to Prostate Cancer Cells. Biomacromolecules, 2017, 18, 2799-2807.	5.4	7
9	Enzyme/Prodrug Systems for Cancer Gene Therapy. Current Pharmacology Reports, 2016, 2, 299-308.	3.0	67
10	Progress and problems with the use of suicide genes for targeted cancer therapy. Advanced Drug Delivery Reviews, 2016, 99, 113-128.	13.7	141
11	Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. Journal of Controlled Release, 2015, 200, 179-187.	9.9	58
12	Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides. Pharmaceutical Research, 2015, 32, 3018-3028.	3.5	22
13	Practical Issues with the Use of Stem Cells for Cancer Gene Therapy. Stem Cell Reviews and Reports, 2015, 11, 688-698.	5.6	9
14	Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1603-1616.	6.4	24
15	Gene-Directed Enzyme Prodrug Cancer Therapy. , 2014, , 77-91.		2
16	Development of a novel histone H1-based recombinant fusion peptide for targeted non-viral gene delivery. International Journal of Pharmaceutics, 2013, 441, 307-315.	5.2	25
17	Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. Journal of Controlled Release, 2013, 172, 179-189.	9.9	28
18	Systematic Engineering of Uniform, Highly Efficient, Targeted and Shielded Viralâ€Mimetic Nanoparticles. Small, 2013, 9, 2774-2783.	10.0	23

#	Article	IF	Citations
19	A Recombinant Biopolymeric Platform for Reliable Evaluation of the Activity of pH-Responsive Amphiphile Fusogenic Peptides. Biomacromolecules, 2013, 14, 2033-2040.	5.4	36
20	Bispecific antibody complex pre-targeted delivery of polymerâ€“drug conjugates for cancer therapy. Drug Delivery and Translational Research, 2012, 2, 65-76.	5.8	13
21	Advances in image-guided drug delivery. Drug Delivery and Translational Research, 2012, 2, 1-2.	5.8	5
22	Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus. Journal of Controlled Release, 2011, 151, 95-101.	9.9	32
23	HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 193-200.	3.3	31
24	Development of recombinant cationic polymers for gene therapy research. Advanced Drug Delivery Reviews, 2010, 62, 1524-1529.	13.7	58
25	Advances in recombinant polymers for delivery of bioactive agents. Advanced Drug Delivery Reviews, 2010, 62, 1403.	13.7	13
26	Advances with the use of bio-inspired vectors towards creation of artificial viruses. Expert Opinion on Drug Delivery, 2010, 7, 497-512.	5.0	27
27	A designer biomimetic vector with a chimeric architecture for targeted gene transfer. Journal of Controlled Release, 2009, 137, 46-53.	9.9	47
28	Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells. Journal of Controlled Release, 2009, 138, 188-196.	9.9	44
29	Development of a Genetically Engineered Biomimetic Vector for Targeted Gene Transfer to Breast Cancer Cells. Molecular Pharmaceutics, 2009, 6, 1100-1109.	4.6	35
30	Perspectives in vector development for systemic cancer gene therapy. Gene Therapy and Molecular Biology, 2009, 13, 15-19.	1.3	20
31	Evaluation of the effect of vector architecture on DNA condensation and gene transfer efficiency. Journal of Controlled Release, 2008, 129, 117-123.	9.9	31